Lacosamide Vivanta (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing these channels, it reduces excessive neuronal firing that leads to seizures, without markedly affecting normal brain activity.

The specific dose and infusion rate of Lacosamide Vivanta are determined by the prescribing clinician based on the patient’s clinical condition, response, and any relevant laboratory values. Dosage adjustments are individualized.

The pregnancy safety category for lacosamide is unknown. Use during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant, and after careful discussion with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional agents that block fast inactivation. This can offer complementary seizure control when combined with other antiepileptics, and it may have a distinct side‑effect profile compared with drugs such as carbamazepine or levetiracetam.

Lacosamide Vivanta should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep the product in its original packaging until ready for use to maintain stability.

The medication is supplied as an intravenous solution and is administered by slow infusion into a vein under the supervision of a qualified healthcare professional. The infusion rate and duration are set by the prescriber according to clinical guidelines.

Serious risks include cardiac arrhythmias such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, and psychiatric effects including suicidal thoughts. Patients should be monitored closely for any of these events, and treatment should be discontinued if they occur.

Lacosamide Vivanta is contraindicated in patients with known hypersensitivity to lacosamide or any component of the formulation. Caution is also advised for individuals with significant cardiac conduction abnormalities, severe renal impairment, or those taking interacting medications that could increase toxicity.